1-(2,6-dimethylphenyl)-4-methylpiperazine | 1438279-35-6

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(2,6-dimethylphenyl)-4-methylpiperazine
• 英文别名: 1-(2,6-dimethylphenyl)-4-methylpiperidine
• CAS: 1438279-35-6
• 化学式: C₁₃H₂₀N₂
• 分子量: 204.315
• InChiKey: NHYJXISUOSCSJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-甲基哌嗪 、 2-氯-1,3-二甲苯 在 C₃₄H₃₉N₃O₄Pd 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.5h， 以95%的产率得到1-(2,6-dimethylphenyl)-4-methylpiperazine
  参考文献：
  名称：

  (IPr)Pd(pydc) (pydc = pyridine-2,6-dicarboxylate) – A highly active precatalyst for the sterically hindered C–N coupling reactions

  摘要：

  A new class of well-defined NHC-Pd complexes incorporating a pyridine-2-carboxylate or pyridine-2,6-dicarboxylate ligand has been synthesized. These novel complexes exhibited prominent catalytic activity in the sterically hindered C-N coupling reactions at elevated temperature, but relatively inferior reactivity at low temperature. The distinctly different reactivity of these NHC-Pd complexes was presumed to be associated with their unique structures of ancillary ligands. (C) 2013 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2013.03.021

文献信息

• IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF
  申请人：IMPACT THERAPEUTICS, INC.

  公开号：US20200131192A1

  公开（公告）日：2020-04-30

  Disclosed are imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R 1 -R 5 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.

  本文揭示了咪唑[1,2-b]嘧啶并[4,5-d]吡啶嗪-5(6H)-酮化合物，具体由公式I表示：或其药用可接受的盐或前药，其中A和R1-R5在此定义。具有公式I的化合物是Wee1激酶抑制剂。因此，本公开的化合物可用于治疗由异常Wee1活性引起的疾病。
• Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use
  申请人：Moinet Christophe

  公开号：US20070043095A1

  公开（公告）日：2007-02-22

  The present invention is drawn to compounds of the formula in racemic and enantiomeric form or all combinations of these forms wherein the various substituents are as defined in the application which compounds have a good affinity for certain subtypes of somatostatin receptors and have useful pharmacological properties.

  本发明涉及公式中的化合物，包括外消旋和对映体形式或这些形式的所有组合，其中各种取代基的定义如申请书所述。这些化合物对某些生长抑素受体亚型具有良好的亲和力，并具有有用的药理学性质。
• 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
  申请人：IMPACT THERAPEUTICS, INC.

  公开号：US10703759B2

  公开（公告）日：2020-07-07

  Disclosed are 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R1-R7 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.

  所公开的是 8,9-二氢咪唑并[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮化合物，具体由式 I 表示： 或其药学上可接受的盐或原药，其中 A 和 R1-R7 在此定义。具有式 I 的化合物是 Wee1 激酶抑制剂。因此，本公开的化合物可用于治疗由 Wee1 活性异常引起的疾病。
• Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof
  申请人：IMPACT THERAPEUTICS (SHANGHAI), INC

  公开号：US11345710B2

  公开（公告）日：2022-05-31

  Disclosed are imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R1-R5 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.

  所公开的是咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮化合物，具体由式 I 表示： 或其药学上可接受的盐或原药，其中 A 和 R1-R5 在此定义。具有式 I 的化合物是 Wee1 激酶抑制剂。因此，本公开的化合物可用于治疗由 Wee1 活性异常引起的疾病。
• 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES
  申请人：IMPACT THERAPEUTICS, INC.

  公开号：US20190308984A1

  公开（公告）日：2019-10-10

  Disclosed are 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R 1 -R 7 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.